Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.65 |
| ▸ | SGK1 | O00141 | 2/20 | 0.47 |
| ▸ | AKT1 | P31749 | 2/20 | 0.47 |
| ▸ | AKT2 | P31751 | 2/20 | 0.47 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4806113 | 0.82 | CHEK1 (0.70) | CHEK1SGK1AKT1AKT2AKT3 | |
| SCHEMBL4817961 | 0.80 | CHEK1 (0.64) | CHEK1AURKACHEK2 | |
| SCHEMBL4814222 | 0.79 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL4808017 | 0.78 | CHEK1 (0.62) | CHEK1 | |
| SCHEMBL4816339 | 0.78 | CHEK1 (0.54) | CHEK1SGK1AKT1AKT2AKT3 | |
| SCHEMBL6992572 | 0.77 | CHEK1 (0.60) | CHEK1SGK1AKT1AKT2AKT3 | |
| SCHEMBL7000003 | 0.76 | CHEK1 (0.64) | CHEK1 | |
| SCHEMBL4813595 | 0.76 | CHEK1 (0.60) | CHEK1 | |
| SCHEMBL4814814 | 0.76 | PDGFRB (0.50) | CHEK1SGK1AKT1AKT2AKT3 | |
| SCHEMBL4814261 | 0.76 | CHEK1 (0.81) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | CHEK1 73/4885SGK1 294/4885AKT1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.